Mr. Hu Yanbao (胡衍保) joined our Group as a senior manager of business development department in November 2020 and was appointed as our Board secretary and joint company secretary in August 2022 and March 22, 2023, respectively. He is primarily responsible for business development, financing, corporate governance and company secretarial matters of our Group.

Prior to joining our Group, from August 2012 to September 2018, Mr. Hu served as the a member and bureau chief of investment promotion bureau at Taizhou Medical High-tech Industrial Park (泰州医药高新技术产业园区), a government institution that focus on promoting the pharmaceutical industry, where he was responsible for investment promotion and business expansion. From October 2018 to October 2020, Mr. Hu served as a deputy general manager at Taizhou China Medical City Rongjianda Venture Capital Management Co., Ltd. (泰州中国医药城融健达创业投资管理有限公司), a state-owned investment company, where he was mainly responsible for equity investment and post-investment services.

Mr. Hu graduated from Beijing University of Chinese Medicine (北京中医药大学) in the PRC in June 2009 with a bachelor’s degree in pharmaceutical engineering. He also obtained a master’s degree of pharmacognosy from Peking Union Medical College (北京协和医学院) in the PRC in July 2012.